Blood Sugar & Metabolic Health: 2026 Physician-Reviewed CGM Guide

Introduction

If you just received a blood sugar result you don’t fully understand — or you’re trying to decide whether a continuous glucose monitor is worth it — this page will give you physician-reviewed answers, not vague reassurances.

What you’ll find here:

• Exactly what normal blood sugar levels mean at fasting and after eating, with ADA 2024 reference ranges
• How continuous glucose monitoring (CGM) works, and how it compares to traditional fingerstick blood glucose meters
• An honest, evidence-graded assessment of OTC CGMs like Dexcom Stelo and Abbott Lingo for people without diabetes
• When blood sugar readings require emergency action — and exactly what to do

Every clinical claim on this page has been reviewed by Dr. Rishav Das, M.B.B.S. This is not medical advice. If you are experiencing hypoglycemia symptoms or an acute blood sugar crisis, seek emergency care immediately.

Important: If your blood sugar is below 70 mg/dL right now, go directly to [The 15-15 Rule →] before reading further.

What Is Metabolic Health?

Metabolic health refers to the body’s ability to efficiently process energy, regulate blood glucose, manage lipids, and maintain healthy blood pressure. Research published in Metabolic Syndrome and Related Disorders suggests that a significant proportion of adults — even those of normal weight — may not meet all criteria for optimal metabolic health [1]. Research published in Metabolic Syndrome and Related Disorders

Reference ranges are general population guidelines. Individual clinical targets may differ — consult your healthcare provider.

Five components commonly associated with metabolic health:

• Absence of medication dependency for the above markers
• Fasting glucose regulation
• Lipid profile balance (triglycerides, HDL, LDL)
• Blood pressure control
• Healthy waist circumference

Blood Sugar Regulation in the Body

Blood glucose regulation is a continuous hormonal process. When carbohydrates are consumed, the digestive system breaks them down into glucose, which enters the bloodstream. The pancreas responds by secreting insulin, a hormone that enables cells to absorb glucose for energy [2]. Carbohydrate digestion process

Key regulatory mechanisms:

• Prolonged fasting triggers gluconeogenesis (glucose synthesis from non-carbohydrate sources)
• The liver stores glucose as glycogen and releases it between meals
• The kidneys filter and reabsorb glucose below a threshold (~180 mg/dL)
• Physical activity increases cellular glucose uptake independent of insulin

Insulin Resistance and Metabolic Syndrome

Insulin resistance occurs when cells in the muscles, liver, and fat tissue respond less effectively to insulin signals, requiring the pancreas to produce increasing amounts to maintain glucose control. Over time, this may exhaust pancreatic beta-cell capacity [3]. Cells respond less effectively to insulin signals

Risk factors associated with insulin resistance (NIH, 2023) [4] clinical guidance on prediabetes :

• Physical inactivity
• Excess adipose tissue, particularly visceral (abdominal) fat
• Diet patterns high in refined carbohydrates and ultra-processed foods
• Family history of Type 2 diabetes
• Sleep deprivation and chronic stress
• Certain medications (e.g., glucocorticoids)

🔗 Related Content: Metabolic syndrome is also associated with elevated cardiovascular risk — see our Heart & Cardiovascular Health pillar for related content.

Type 1, Type 2, and Gestational Diabetes

All three conditions require individualized medical management. Classification and treatment should be determined by a licensed healthcare provider.

What Is a Normal Blood Sugar Level?

Normal fasting blood sugar is 70–99 mg/dL. A fasting reading of 100–125 mg/dL indicates prediabetes; 126 mg/dL or higher on two separate tests meets the diagnostic threshold for diabetes, per ADA 2024 Standards of Care. After eating, blood sugar below 140 mg/dL at 2 hours post-meal is considered normal for adults without diabetes.

Normal fasting blood sugar is 70–99 mg/dL. A fasting reading of 100–125 mg/dL indicates prediabetes; 126 mg/dL or higher on two separate tests meets the diagnostic threshold for diabetes, per ADA 2024 Standards of Care. After eating, blood sugar below 140 mg/dL at 2 hours post-meal is considered normal for adults without diabetes.

The table below breaks down these ranges by category and testing context:

Source: American Diabetes Association Standards of Care, 2024 [6] These ranges represent general diagnostic thresholds. Individual target ranges for people with existing diabetes may differ significantly based on age, comorbidities, and treatment plan.

What Causes a Postprandial Glucose Spike?

What is HbA1c and Why does it matter?

HbA1c (glycated hemoglobin or A1C) reflects average blood glucose over approximately 2–3 months by measuring the percentage of hemoglobin with attached glucose molecules [8]. Glycated hemoglobin testing

ADA target for most non-pregnant adults with diabetes: below 7.0% [6] American Diabetes Association Standards of Care, 2024 . Individualized targets may differ based on patient factors.

Limitations of HbA1c:

• Ethnic variation in HbA1c levels has been documented in the literature [9]. Ethnic variation in HbA1c levels has been documented
• May be unreliable in individuals with certain hemoglobin variants or hemolytic anemias
• Does not capture glucose variability or hypoglycemia episodes
• Does not reflect short-term glucose changes

Hypoglycemia vs. Hyperglycemia

⚠️ Safety Callout: Severe hypoglycemia and DKA/HHS are medical emergencies. Do not attempt to self-manage — call emergency services immediately.

Type 1 Diabetes (Medical Necessity)

Glucose monitoring is not optional for individuals with Type 1 diabetes — it is a medical requirement for safe management.

Type 2 Diabetes and Treatment Regimens

The need for glucose monitoring in Type 2 diabetes varies significantly based on treatment regimen.

Monitoring frequency and targets should always be established by the treating physician or diabetes care team.

Prediabetes and Prevention

Evidence suggests that structured lifestyle intervention in people with prediabetes can significantly reduce progression to Type 2 diabetes [10]. Proven lifestyle interventions

🔗 Related Content: Physical activity and body composition may influence insulin sensitivity — see the Fitness & Activity and Body Composition pillars.

General Metabolic Health Awareness

For individuals without a diabetes diagnosis or significant metabolic risk, the clinical evidence supporting routine glucose monitoring is limited.

Working With Your Healthcare Team

✅ Key Message: Glucose monitoring is most clinically valuable when integrated into a coordinated care plan.

The team composition will vary based on individual diagnosis, complexity, and healthcare access.

Blood Glucose Meters (BGM): How They Work and When to Use Them

Traditional blood glucose meters (BGMs) measure glucose from a small capillary blood sample obtained via fingerstick.

Advantages:

• Widely available and affordable
• No sensor warmup period
• Used to calibrate CGM devices in some systems
• Remains the standard for confirming CGM readings before treatment decisions

Limitations:

• Does not capture glucose variability or nocturnal changes
• Provides no trend information
• Requires repeated fingersticks
• Pain and burden may reduce adherence

Continuous Glucose Monitors (CGM): Real-Time Tracking for Diabetes Management

Continuous glucose monitors measure interstitial fluid glucose at frequent intervals, providing real-time readings, trend arrows, and pattern data.

🔗 Related Content: For a detailed comparison of CGM systems including accuracy data, insurance coverage, and prescription requirements, see our Glucose Monitoring Device Guide.

Flash Glucose Monitoring (FGM): Scanning vs. Streaming

Flash glucose monitoring (FGM) uses a sensor similar to CGM but requires the user to scan the sensor to obtain a reading rather than providing automatic continuous transmission.

The clinical distinction between FGM and CGM has narrowed with newer FreeStyle Libre iterations, which may include automatic readings in some configurations.

Non-Invasive Monitoring (Limited Availability)

Non-invasive glucose monitoring technologies — which aim to measure glucose without skin penetration — are an active area of research and development. As of 2024, no FDA-cleared non-invasive continuous glucose monitor is available for general consumer use in the United States [12]. FDA warns against uncleared glucose monitoring devices

⚠️ Regulatory Caution: The FDA has issued warnings about smartwatches and rings that claim to measure blood glucose non-invasively without FDA clearance. These devices should not be used for diabetes management decisions [12].

Who Can Use an OTC CGM Without a Prescription?

Adults 18 and older can purchase Dexcom Stelo or Abbott Lingo without a prescription, regardless of diabetes status. Dexcom Stelo is intended for adults with or without diabetes who are not on insulin; Abbott Lingo is intended for adults without diabetes who want to monitor how diet, exercise, and lifestyle affect their glucose. Neither device is intended for people with diabetes who use insulin or are at risk of severe hypoglycemia — those individuals should continue using prescription CGMs such as the Dexcom G7 or FreeStyle Libre 3 under physician guidance.

Dexcom Stelo vs. Abbott Lingo: Side-by-Side Comparison

Dexcom Stelo and Abbott Lingo were both cleared by the FDA in 2024 for OTC use, but they differ in cost, sensor wear time, and intended audience. The table below compares both devices directly.

COMPARISON TABLE

Note: Verify current pricing and FDA labeling against manufacturer sources before publishing — OTC CGM pricing and indications are subject to change.

Is a CGM Worth It for Non-Diabetics? Honest Evidence Assessment

Clinical evidence that continuous glucose monitoring improves health outcomes in people without diabetes is currently limited. While Dexcom Stelo and Abbott Lingo are FDA-cleared for OTC use by adults 18+ without a prescription, no large randomized controlled trial has demonstrated that non-diabetic users achieve better metabolic outcomes from CGM use than from standard dietary monitoring alone. Dr. Rishav Das recommends that non-diabetic individuals discuss CGM use with a physician before purchasing.

Clinical evidence that continuous glucose monitoring improves health outcomes in people without diabetes is currently limited.

While Dexcom Stelo and Abbott Lingo are FDA-cleared for OTC use by adults 18+ without a prescription, no large randomized controlled trial has demonstrated that non-diabetic users achieve better metabolic outcomes from CGM use than from standard dietary monitoring alone.

Dr. Rishav Das recommends that non-diabetic individuals discuss CGM use with a physician before purchasing.

Normal Blood Sugar Ranges by Category

Source: ADA Standards of Medical Care in Diabetes, 2024 [6]. Individualized targets should be set by the treating provider.

What Is a Good Time in Range (TIR) Score?

Time in Range (TIR) measures the percentage of time a person’s glucose stays within 70–180 mg/dL. The American Diabetes Association recommends a TIR above 70% for most adults with Type 1 or Type 2 diabetes — meaning glucose is in the target zone for more than 17 hours per day. A TIR below 70% is associated with increased risk of diabetes complications including retinopathy and neuropathy.

Time in Range (TIR) measures the percentage of time your glucose stays within a target range — typically 70–180 mg/dL. The American Diabetes Association recommends a TIR above 70% for most people with Type 1 or Type 2 diabetes, meaning your glucose is in the safe zone for more than 17 hours per day. A TIR below 70% is associated with increased risk of diabetes complications including retinopathy and neuropathy.

The table below shows the full ADA 2024 targets for TIR, Time Below Range (TBR), and Time Above Range (TAR) — the three metrics most CGM apps display on your daily summary

Time in Range (TIR) is a metric derived from CGM data that measures the percentage of time glucose levels remain within a clinically defined target range.

Source: Battelino et al., Diabetes Care, 2019 [13]

Glucose variability refers to fluctuations in glucose levels beyond the average. High variability may be associated with increased oxidative stress and cardiovascular risk, independent of A1C, though evidence is still developing in this area [14].

Understanding HbA1c: What Does Your A1C Number Mean?

An HbA1c of 6.5% or higher on two separate tests is the diagnostic threshold for diabetes, per ADA 2024 Standards of Care. An HbA1c of 5.7–6.4% indicates prediabetes. A result of 6.5% specifically means your average blood sugar over the past 2–3 months was approximately 140 mg/dL — the equivalent of blood sugar consistently at the high end of the normal-after-eating range.

The table below shows how each HbA1c range is classified and what it means for your care plan.

A new prediabetes or diabetes diagnosis based on an HbA1c result can feel overwhelming, especially if your fasting glucose numbers seemed normal. The good news is that an A1C in the prediabetes range is reversible for many people through diet, exercise, and weight management — and understanding your number is the first step toward acting on it.

Understanding Glucose Patterns and Variations

Meaningful glucose management involves pattern recognition over time, not reaction to isolated readings.

CGM and BGM for Type 1 Diabetes

The ADA recommends CGM as the standard of care for most individuals with Type 1 diabetes [6].

CGM and BGM for Type 2 Diabetes and Prediabetes

Frequency recommendations should be individualized. Insurance coverage and accessibility are important practical considerations.

CGM Insurance Coverage: What Type 2 Patients Need to Know

Medicare and most private insurers cover prescription CGMs — such as the Dexcom G7 and FreeStyle Libre 3 — for people with Type 2 diabetes who use insulin or who have documented episodes of hypoglycemia, with a prescription from their healthcare provider.

Coverage criteria for Type 2 patients who are not on insulin vary significantly by plan and have been expanding in recent years, so the most reliable first step is to ask your prescribing physician’s office to run a coverage check (often called a “benefits investigation”) before purchasing.

Over-the-counter CGMs like Dexcom Stelo and Abbott Lingo are generally not covered by insurance, since they are marketed as wellness devices rather than prescription medical devices — but they also do not require a prescription, prior authorization, or a diabetes diagnosis to purchase.

Physician note: Coverage rules change frequently and vary by insurer and plan. This section reflects general patterns as of 2026 and should not be used to predict your individual coverage — contact your insurer or your prescriber’s office directly to confirm current criteria for your plan

Insurance coverage information changes frequently and varies by payer. Verify current coverage with your insurance plan and the CGM manufacturer’s coverage support team.

Sharing Data With Healthcare Providers

Modern CGM systems facilitate data sharing through cloud-based platforms, enabling remote review by the care team.

Best practices for data sharing:

• Bring meter readings if fingerstick is used as backup
• Download or sync CGM data before every clinic appointment
• Share access with care team between appointments if clinically indicated
• Review reports together; ask for explanation of any pattern adjustments

Insulin Resistance and HOMA-IR: Early Warning Signs

Insulin resistance occurs when your body’s cells respond less effectively to insulin, requiring the pancreas to produce more of it to keep blood sugar stable. It often develops years before blood sugar levels rise high enough to be classified as prediabetes or diabetes — which is why it’s frequently called a “silent” early warning sign.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a lab calculation derived from fasting glucose and fasting insulin levels. A HOMA-IR score below 2.0 is generally considered normal; higher scores suggest increasing insulin resistance and elevated risk of developing Type 2 diabetes over time.

Common signs associated with insulin resistance include increased abdominal (visceral) fat, fatigue after meals, difficulty losing weight despite diet changes, and skin changes such as acanthosis nigricans (darkened skin in body folds). None of these signs alone confirms insulin resistance — a fasting insulin and glucose panel from your healthcare provider is needed for diagnosis.

Because visceral fat is closely linked to insulin resistance, body composition tracking can provide an additional early signal — see our [best smart scale for body fat percentage accuracy] guide for more on tracking visceral fat at home

Do Smartwatches Measure Blood Sugar? What the FDA Says

As of 2026, no smartwatch or smart ring is FDA-cleared to measure blood glucose without piercing the skin. In February 2024, the FDA issued an explicit warning that non-invasive glucose monitoring claims by consumer smartwatches are unproven and should not be used for diabetes management decisions. The only cleared blood sugar monitoring options available over the counter are subcutaneous CGM sensors: Dexcom Stelo and Abbott Lingo (both cleared in 2024 for adults 18+ without a prescription).

No. As of 2026, no smartwatch or smart ring is FDA-cleared to measure blood glucose without piercing the skin. In February 2024, the FDA issued an explicit safety warning stating that non-invasive glucose monitoring features in smartwatches and smart rings are unproven and potentially dangerous for anyone making diabetes management decisions. The only cleared blood sugar monitoring devices are fingerstick meters (BGM) and subcutaneous CGM sensors like the Dexcom G7, FreeStyle Libre 3, Dexcom Stelo, and Abbott Lingo.

Discuss appropriate testing frequency and interpretation with your primary care provider or endocrinologist.

Can Healthy People Benefit From Glucose Monitoring?

The use of CGM in people without diabetes has grown significantly since OTC availability increased in 2024. The clinical evidence for benefit in non-diabetic populations, however, remains limited and is an active area of investigation.

Food Response and Metabolic Variability

Research published in Cell by Zeevi et al. (2015) demonstrated that glycemic responses to identical foods vary substantially between individuals, influenced by gut microbiome composition, genetics, sleep, and physical activity [11]. Research published in Cell

⚠️ This section contains critical medical safety information. Please review it carefully.

When to Call a Doctor About Your Blood Sugar

Blood sugar below 54 mg/dL (severe hypoglycemia) or above 300 mg/dL requires emergency medical care. A reading below 70 mg/dL indicates mild hypoglycemia and should be treated immediately with 15 grams of fast-acting carbohydrates. If you cannot treat yourself, are unconscious, or glucose does not recover after two treatment cycles, call emergency services (911) immediately.

Blood sugar below 54 mg/dL (severe hypoglycemia) or above 300 mg/dL requires emergency medical care. A reading below 70 mg/dL indicates mild hypoglycemia and should be treated immediately with 15 grams of fast-acting carbohydrates. If you cannot treat yourself, are unconscious, or glucose does not recover after two treatment cycles, call emergency services (911) immediately.

The table below outlines every threshold and the recommended response.

The 15-15 Rule for Low Blood Sugar: Step-by-Step

To treat low blood sugar (below 70 mg/dL), follow the 15-15 rule: (1) Consume 15 grams of fast-acting carbohydrates — 4 glucose tablets, 4 ounces of orange juice, or 3–4 pieces of hard candy. (2) Wait 15 minutes. (3) Recheck blood sugar. (4) If still below 70 mg/dL, repeat steps 1–3. (5) If glucose does not respond or you feel unable to treat yourself, call 911 immediately.

To treat low blood sugar (below 70 mg/dL), follow the 15-15 rule:

1. Consume 15 grams of fast-acting carbohydrates — 4 glucose tablets, 4 ounces of orange juice, or 3–4 pieces of hard candy.
2. Wait 15 minutes.
3. Recheck your blood sugar.
4. If still below 70 mg/dL, repeat steps 1–3.
5. If your glucose does not respond after two cycles, or you feel unable to treat yourself, call 911 immediately

Symptoms by severity:

Source: ADA Standards of Care, 2024 [6]

⚠️ Do not give food or drink to someone who is unconscious or unable to swallow. This is a medical emergency — call 911.

When to Consult a Healthcare Provider

This educational content was developed to support health literacy, not to replace individualized medical guidance. Consider consulting a healthcare provider if you:

• Have been diagnosed with diabetes, prediabetes, or metabolic syndrome
• Have a family history of Type 2 diabetes or cardiovascular disease
• Are considering using a continuous glucose monitor, including OTC options
• Have questions about your glucose readings or A1C results
• Are experiencing symptoms that may indicate hypoglycemia or hyperglycemia
• Are pregnant or planning pregnancy and have any blood sugar concerns
• Want to assess your metabolic health with validated laboratory testing

See our About page for information on the medical oversight standards that govern this content.

Ready to Take the Next Step?

Based on what you’ve read, choose the resource that matches your situation:

→ Just diagnosed or interpreting your numbers? Start with our Glucose Metrics Explained guide — it translates every metric your doctor uses into plain language.

→ Comparing CGM devices for diabetes management? See our Glucose Monitoring Device Guide, reviewed by Dr. Rishav Das with FDA-clearance status for every major device.

→ Choosing between Dexcom Stelo, Abbott Lingo, and FreeStyle Libre? Our CGM Device Comparison covers cost, accuracy, and evidence grade side by side.

→ Thinking about a glucose monitor but not sure which type? The Glucose Monitor Buying Guide walks you through the decision by diagnosis type and insurance status.

Not ready to buy? Save this page and consult with your physician before purchasing any glucose monitoring device.

References

1. Araújo J, Cai J, Stevens J. Prevalence of optimal metabolic health in American adults: National Health and Nutrition Examination Survey 2009–2016. Metabolic Syndrome and Related Disorders. 2019;17(1):46–52. PubMed
   
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The Digestive System and How It Works. U.S. Department of Health and Human Services. Available at: https://www.niddk.nih.gov
   
3. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiological Reviews. 2018;98(4):2133–2223. PubMed
   
4. National Institutes of Health (NIH). Insulin Resistance & Prediabetes. NIDDK. Updated 2023. Available at: https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance
   
5. Centers for Disease Control and Prevention (CDC). Gestational Diabetes. Updated 2023. Available at: https://www.cdc.gov/diabetes/basics/gestational.html
   
6. American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement 1). Available at: https://diabetesjournals.org/care/issue/47/Supplement_1
   
7. Cavalot F, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in Type 2 diabetes mellitus. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):813–819. PubMed
   
8. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The A1C Test & Diabetes. Updated 2023. Available at: https://www.niddk.nih.gov/health-information/diagnostic-tests/a1c-test
   
9. Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. Journal of Clinical Endocrinology & Metabolism. 2012;97(4):1067–1072. PubMed
   
10. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346(6):393–403. PubMed
    
11. Zeevi D, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163(5):1079–1094. PubMed
    
12. U.S. Food and Drug Administration (FDA). FDA Warns Against Using Smartwatches or Smart Rings That Claim to Measure Blood Glucose Levels Without Piercing the Skin. February 2024. Available at: https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-using-smartwatches-or-smart-rings-claim-measure-blood-glucose-levels-without
    
13. Battelino T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–1603. PubMed
    
14. Gorst C, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354–2369. PubMed
    
15. Bergenstal RM, et al. Continuous glucose monitoring for type 2 diabetes in various health care settings. New England Journal of Medicine. 2021;384(18):1677–1687. PubMed
    

Buxton OM, et al. Sleep restriction for 1 week reduces insulin sensitivity in healthy men. Diabetes. 2010;59(9):2126–2133. PubMed

⚠️ Medical Disclaimer: This content is for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Do not adjust diabetes medication or insulin without direct guidance from a licensed healthcare provider. If you are experiencing a medical emergency related to blood sugar, call emergency services immediately.

See our editorial review standards and conflict-of-interest and funding policy for full methodology and procurement transparency.

For complete medical oversight and review scope, including safety disclosures and scope limitations, see our About page.

Last Updated: June,2026